Format

Send to

Choose Destination
Immun Inflamm Dis. 2016 Apr 1;4(2):135-147. eCollection 2016 Jun.

Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.

Author information

1
Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
2
Pfizer Vaccine Immunotherapeutics La Jolla California USA.
3
Pfizer Biotherapeutics Pharmaceutical Sciences St. Louis Missouri USA.

Abstract

The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Cϵ3) of free human IgE in the blood and interstitial fluid. Although efficacious, use of omalizumab is limited due to restrictions on patient weight and pre-existing IgE levels, and frequent dosing (q2-4 weeks). A vaccine inducing anti-IgE antibodies has the potential for similar clinical benefits with less frequent dosing and relatively lower cost of goods. We developed a vaccine containing two IgE peptide-conjugates targeting the Cϵ3 domain of human IgE. As part of preclinical evaluation of the vaccine to optimize formulation and dose prior to initiating clinical studies, we evaluated the vaccine in non-human primates, and demonstrate the induction of anti-peptide antibodies that can bind to conformationally intact human IgE and are capable, at least in some animals, of substantial lowering circulating IgE levels.

KEYWORDS:

Allergy; IgE; IgE peptide conjugates; anti‐IgE antibodies; vaccine

PMID:
27957325
PMCID:
PMC4879460
DOI:
10.1002/iid3.98
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center